HRP20240858T1 - Kristal spoja oksazola - Google Patents

Kristal spoja oksazola Download PDF

Info

Publication number
HRP20240858T1
HRP20240858T1 HRP20240858TT HRP20240858T HRP20240858T1 HR P20240858 T1 HRP20240858 T1 HR P20240858T1 HR P20240858T T HRP20240858T T HR P20240858TT HR P20240858 T HRP20240858 T HR P20240858T HR P20240858 T1 HRP20240858 T1 HR P20240858T1
Authority
HR
Croatia
Prior art keywords
crystal
infrared absorption
measured
peaks
rays
Prior art date
Application number
HRP20240858TT
Other languages
English (en)
Croatian (hr)
Inventor
Naohiko KANAI
Takayuki YASUTOMI
Ryosuke HIROTA
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of HRP20240858T1 publication Critical patent/HRP20240858T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20240858TT 2018-04-04 2019-04-03 Kristal spoja oksazola HRP20240858T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018072717 2018-04-04
PCT/JP2019/014730 WO2019194211A1 (en) 2018-04-04 2019-04-03 Oxazole compound crystal
EP19718465.8A EP3774745B1 (en) 2018-04-04 2019-04-03 Oxazole compound crystal

Publications (1)

Publication Number Publication Date
HRP20240858T1 true HRP20240858T1 (hr) 2024-10-11

Family

ID=66223774

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240858TT HRP20240858T1 (hr) 2018-04-04 2019-04-03 Kristal spoja oksazola

Country Status (26)

Country Link
US (4) US11414391B2 (cg-RX-API-DMAC7.html)
EP (2) EP4400167A3 (cg-RX-API-DMAC7.html)
JP (4) JP7326295B2 (cg-RX-API-DMAC7.html)
KR (2) KR102764726B1 (cg-RX-API-DMAC7.html)
CN (1) CN111902402B (cg-RX-API-DMAC7.html)
AU (2) AU2019249562B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019377A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095866A1 (cg-RX-API-DMAC7.html)
DK (1) DK3774745T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092393A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982586T3 (cg-RX-API-DMAC7.html)
FI (1) FI3774745T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240858T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066793T2 (cg-RX-API-DMAC7.html)
IL (2) IL315425A (cg-RX-API-DMAC7.html)
LT (1) LT3774745T (cg-RX-API-DMAC7.html)
MX (1) MX2020010435A (cg-RX-API-DMAC7.html)
MY (1) MY202406A (cg-RX-API-DMAC7.html)
PH (1) PH12020551605A1 (cg-RX-API-DMAC7.html)
PL (1) PL3774745T3 (cg-RX-API-DMAC7.html)
PT (1) PT3774745T (cg-RX-API-DMAC7.html)
SG (1) SG11202009564TA (cg-RX-API-DMAC7.html)
SI (1) SI3774745T1 (cg-RX-API-DMAC7.html)
TW (2) TWI860993B (cg-RX-API-DMAC7.html)
WO (1) WO2019194211A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006134B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3774745T3 (pl) * 2018-04-04 2024-08-19 Otsuka Pharmaceutical Co., Ltd. Kryształ cząsteczki oksazolu
EP4501324A4 (en) 2022-03-25 2026-04-08 Otsuka Pharma Co Ltd WOUND TREATMENT COMPOSITION
CN115887463A (zh) * 2022-12-27 2023-04-04 瑞石生物医药有限公司 一种含环酰胺化合物的药物组合物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
US20260076788A1 (en) * 2024-09-17 2026-03-19 Natalie DeVoir Orthodontic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330639B (en) * 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
EP2890686B1 (en) * 2012-08-30 2017-01-04 Otsuka Pharmaceutical Co., Ltd. Method for producing oxazole compound
TWI726027B (zh) * 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 軟膏
PL3774745T3 (pl) * 2018-04-04 2024-08-19 Otsuka Pharmaceutical Co., Ltd. Kryształ cząsteczki oksazolu

Also Published As

Publication number Publication date
AU2019249562B2 (en) 2024-06-27
AU2024220015A1 (en) 2024-10-17
MX2020010435A (es) 2020-10-28
CA3095866A1 (en) 2019-10-10
IL277730B1 (en) 2024-10-01
IL315425A (en) 2024-11-01
JP2024001115A (ja) 2024-01-09
WO2019194211A1 (en) 2019-10-10
TW202012380A (zh) 2020-04-01
EP4400167A2 (en) 2024-07-17
US20250250243A1 (en) 2025-08-07
EP3774745B1 (en) 2024-05-29
EP3774745A1 (en) 2021-02-17
ZA202006134B (en) 2023-03-29
IL277730B2 (en) 2025-02-01
AU2019249562A1 (en) 2020-10-22
KR20250022254A (ko) 2025-02-14
US20210147370A1 (en) 2021-05-20
JP2021517111A (ja) 2021-07-15
PH12020551605A1 (en) 2021-04-26
TW202515853A (zh) 2025-04-16
JP7326295B2 (ja) 2023-08-15
LT3774745T (lt) 2024-07-10
CN111902402A (zh) 2020-11-06
JP2025128238A (ja) 2025-09-02
SI3774745T1 (sl) 2024-08-30
US20240076275A1 (en) 2024-03-07
IL277730A (en) 2020-11-30
JP2022037040A (ja) 2022-03-08
BR112020019377A2 (pt) 2021-01-05
CN111902402B (zh) 2026-07-14
SG11202009564TA (en) 2020-10-29
FI3774745T3 (fi) 2024-06-19
PL3774745T3 (pl) 2024-08-19
ES2982586T3 (es) 2024-10-16
US11840512B2 (en) 2023-12-12
EP4400167A3 (en) 2024-09-25
US20220411386A1 (en) 2022-12-29
PT3774745T (pt) 2024-06-25
HUE066793T2 (hu) 2024-09-28
EA202092393A1 (ru) 2021-01-25
TWI860993B (zh) 2024-11-11
US11414391B2 (en) 2022-08-16
MY202406A (en) 2024-04-27
KR102764726B1 (ko) 2025-02-11
AU2024220015B2 (en) 2026-03-26
DK3774745T3 (da) 2024-06-17
KR20200139736A (ko) 2020-12-14

Similar Documents

Publication Publication Date Title
HRP20210507T1 (hr) Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku
FI3774745T3 (fi) Oksatsoliyhdistekide
MX373612B (es) Cristal del compuesto alquinil benceno 3,5-disustituido.
HRP20210748T1 (hr) Postupak priprave spojeva s aktivnošću inhibitora hiv integraze
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
JP2014526498A5 (cg-RX-API-DMAC7.html)
AR077242A1 (es) Formas cristalinas del 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}n-(metilsulfonil)acetamida, composiciones farmaceuticas que las contienen, metodo para prepararlas y uso de las mismas en el tratamiento de isquemias, insuficiencia coronaria y asma, entre otras enfermedades.
FI3977993T3 (fi) 6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä
HRP20130026T1 (hr) Kristalni oblik posakonazola
RU2017141763A (ru) Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида
HRP20120662T1 (hr) Termodinamički stabilni oblik bay 43-9006 tosilata
HRP20170540T1 (hr) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
EA200601273A1 (ru) Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат
JP2022037040A5 (cg-RX-API-DMAC7.html)
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
WO2014136282A8 (en) Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
RU2019130768A (ru) Способ получения твердого электролита на основе lgps
WO2019235725A8 (ko) 유기 광전자 소자용 화합물,유기 광전자 소자용 조성물,유기광전자 소자 및 표시 장치
JP2021517111A5 (cg-RX-API-DMAC7.html)
HRP20251307T1 (hr) Kristalni oblik trietilentetramin tetrahidroklorida i njegova farmaceutska upotreba
Golovnev et al. The cis–trans isomer transformation, spectroscopic and thermal properties of Li, Na, K 1, 3-diethyl-2-thiobarbiturate complexes
PH12019502588A1 (en) Crystal form c of sanzuohuangcaotong, preparation method and use thereof
CN103724307A (zh) 含笑内酯二甲基胺富马酸盐的晶型及制备方法
NZ711191A (en) Benzo-fused heterocyclic derivatives useful as agonists of gpr120
Gao et al. Highly selective detection of Hg2+ ion by push–pull-type purine nucleoside-based fluorescent sensor